Overview

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ossium Health, Inc.

Collaborator:

Center for International Blood and Marrow Transplant Research

Treatments:

Busulfan
Cyclophosphamide
Fludarabine
Mycophenolic Acid
Tacrolimus